| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Cash Flows (used in) from Operating Activities: | | | | | | | | |
| Net loss | -745.1 | -488.9 | -428.4 | -126.2 | -79.0 | -100.7 | -116.7 | -188.2 |
| Adjustments to reconcile net loss to net cash (used in) from operating activities: | | | | | | | | |
| Depreciation and amortization expense | 106.2 | 98.8 | 90.6 | 82.9 | 74.5 | 62.6 | 49.4 | 30.7 |
| Change in fair value of contingent consideration | -10.5 | -4.5 | -5.0 | -17.1 | -21.9 | -16.6 | -11.7 | -4.2 |
| Change in fair value of warrant liabilities | -15.8 | -47.6 | -72.8 | -50.0 | -101.0 | -110.1 | -82.9 | -24.6 |
| Loss on extinguishment of debt | | | | | | 14.5 | 13.1 | |
| Fixed asset abandonment | 1.7 | | | | | | | |
| Amortization of debt issuance costs | 4.8 | 4.2 | 3.8 | 3.5 | -2.1 | 3.5 | 4.9 | 4.2 |
| Non-cash lease expense | 4.5 | 5.6 | 6.5 | 8.4 | 3.6 | 1.7 | | |
| Stock-based compensation, net | 34.5 | 50.3 | 54.8 | 57.5 | 55.9 | 41.7 | 28.0 | 13.1 |
| Paid in kind interest expense | 7.4 | 2.1 | | | | | | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable, net | 87.5 | -56.9 | -106.7 | -65.6 | -76.3 | -66.5 | -15.1 | -55.8 |
| Other assets | 2.2 | 13.0 | 10.1 | 4.2 | -3.5 | -18.8 | -16.6 | -12.6 |
| Prepaid expenses and other current assets | -33.2 | -57.1 | -51.7 | -36.7 | -13.3 | -3.5 | -11.8 | -27.8 |
| Interest accrued due to sellers | | | | | 0.6 | 1.0 | 1.5 | 1.2 |
| Accounts payable and accrued expenses | 70.3 | 34.1 | 32.6 | 24.1 | 9.9 | 37.8 | 33.7 | 40.6 |
| Other liabilities | -11.7 | -17.7 | -7.6 | 2.7 | 8.3 | 12.1 | 5.5 | 6.3 |
| Net cash (used in) provided by operating activities | -109.1 | -138.6 | -146.3 | -107.7 | -142.1 | -140.5 | -118.0 | -103.2 |
| |
| Cash Flows (used in) from Investing Activities: | | | | | | | | |
| Purchase of property and equipment | -40.4 | -46.8 | -49.5 | -50.2 | -47.1 | -39.5 | -34.4 | -35.3 |
| Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired | | | -5.8 | | -460.9 | -1,072.9 | -1,070.3 | -1,273.1 |
| Payments to sellers | -11.4 | -11.0 | -8.8 | -6.5 | -6.5 | -22.6 | -26.6 | -77.3 |
| Net cash (used in) provided by investing activities | -52.6 | -60.2 | -64.2 | -66.6 | -514.4 | -1,135.0 | -1,131.2 | -691.2 |
| |
| Cash Flows (used in) from Financing Activities: | | | | | | | | |
| Payments of long-term debt | -6.4 | -6.4 | -6.4 | -6.5 | -258.6 | -658.3 | -657.9 | -975.0 |
| Debt issuance costs | -9.3 | -9.2 | | | -6.2 | -17.5 | -17.4 | -47.6 |
| Proceeds from long-term debt | | 150.0 | | | | | | 1,120.0 |
| Proceeds from CS Revolving Line of Credit | 164.0 | 124.0 | 109.0 | 25.0 | | | | 0.0 |
| Repayments of CS Revolving Line of Credit | -154.0 | -124.0 | | -25.0 | | | | -9.7 |
| Proceeds from insurance financing arrangements | | 2.7 | | | | 2.5 | 1.7 | |
| Payments of principal on insurance financing arrangements | -2.6 | -2.6 | -2.5 | -2.4 | -2.1 | -1.8 | -1.7 | -4.3 |
| Other | -1.7 | -2.8 | | | -1.6 | 0.5 | | 0.1 |
| Net cash (used in) provided by financing activities | 141.6 | 130.6 | 74.7 | -10.6 | 385.1 | 1,382.0 | 1,378.6 | 972.5 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -20.1 | -68.2 | -135.8 | -184.8 | -271.4 | 79.2 | | |
| |
| Cash, cash equivalents and restricted cash at beginning of year | | | | | | | | |
| Cash, cash equivalents and restricted cash at end of period | | | | | | | | |
| Supplemental cash flow information: | | | | | | | | |
| Interest paid | 74.0 | 81.9 | 61.2 | 52.0 | 57.6 | 38.1 | 41.8 | 28.1 |
| Income taxes paid | | | 0.6 | | 1.2 | 1.2 | | 1.2 |
| Non-cash investing and financing activities: | | | | | | | | |
| Right-of-use assets obtained in exchange of lease liabilities | 38.2 | 57.0 | 71.9 | 58.6 | 50.3 | 25.7 | | |
| Issuance of Class A common stock for acquisitions | 37.9 | 37.8 | 39.3 | 57.9 | | 80.2 | 64.5 | 61.5 |
| Due to sellers in connection with acquisitions | | | | 0.0 | 3.2 | 0.1 | | 0.0 |
| Addition to construction in process funded through accounts payable | -2.7 | -2.1 | | 0.0 | 3.6 | 3.0 | | |
| Humana Affiliate Provider clinic leasehold improvements | -2.6 | -1.7 | | 0.0 | 0.1 | 1.1 | | 0.0 |
| Employee Stock Purchase Plan issuance | | 1.1 | | | | 9.7 | | |